Improved Metabolic Markers Both compounds independently improve metabolic health indicators
Participants in the phase 2 trial lost an average of 7 kg (15 lbs) after 16 weeks, significantly more than the placebo group
Rodriguez had constipation, nausea, and headaches, but they're manageable, she said
Most Likely to Benefit Men with obesity and low testosterone Patients with insulin resistance or prediabetes Men with metabolic syndrome Individuals with borderline or mild testosterone deficiency Less Likely to Benefit Men with primary hypogonadism Patients with pituitary disorders Men with genetic or testicular causes of low testosterone In these cases, testosterone therapy is often necessary
Claims described in this article as "according to the brand" or "brand-stated" or "per Omzo's published materials" reflect what Omzo has publicly stated and have not been independently substantiated by this publication
Use of GLP1 medications, together with research into new therapeutic applications, is fueling a multimillion-dollar market built around this breakthrough.
